{"name":"RxSight","slug":"rxsight","ticker":"RXST","exchange":"NASDAQ","domain":"rxsight.com","description":"RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in A","hq":"Aliso Viejo, CA","founded":0,"employees":"461","ceo":"Ron Kurtz","sector":"Ophthalmic Devices / Cataract Surgery","stockPrice":7.17,"stockChange":0.41,"stockChangePercent":6.07,"marketCap":"$296M","metrics":{"revenue":134479000,"revenueGrowth":-18.9,"grossMargin":76.6,"rdSpend":38549000,"netIncome":-38944000,"cash":228128000,"dividendYield":0,"peRatio":-14.8,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"RxSight Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"RxSight reported its financial results for the fourth quarter and full year 2023, with revenue growth and strong performance in key markets.","drugName":"","sentiment":"positive"},{"date":"2023-11-14","type":"deal","headline":"RxSight Announces Strategic Partnership with Leading Eye Care Provider","summary":"RxSight has entered into a strategic partnership with a leading eye care provider to expand its reach and improve patient access to its products.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"RxSight Receives FDA Clearance for New Cataract Surgery Device","summary":"RxSight has received FDA clearance for its new cataract surgery device, which is designed to improve surgical outcomes and patient experiences.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQT3dFOG5jR05ob3JPMkFXWDBhcU8wZXF1REx2OEhIeDM0V2E4NFl2bW1Qb3dUdUV1S2I3ZldiUlY2ZWJvTE9LZlgtSmg4TkhlWmdiZXFKSmJOMzA2TUp1ZlBHalB5OTNzVFp6bzVTNzhBeHRYNUNKQ2huSll3OUZUNWMtbEFOM2xpVHgtRE5zS1d4aWVvdlJPUkliUUljQ3RSOC1aLTJnSFYteVpjS2c?oc=5","date":"2026-03-19","type":"pipeline","source":"Stock Titan","summary":"RxSight (NASDAQ: RXST) details CFO sign-on bonus and corrects option vesting - Stock Titan","headline":"RxSight (NASDAQ: RXST) details CFO sign-on bonus and corrects option vesting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNWjZzaG5qSzlhM0NVQThHRmM3bGg3Y2NoT3Z1OWMyMnp3LXdNOFFxWmVXVjhveDNKYXV4MlhsTUVkbVJnVE5xQnNoQkp1SGJJSVZhRFBUdFpSX0g4YXdqSkpnYzVxWVFLWjIzemR4TmFkU0NKWl81SWJfeVkzcTNhaUhOdjM5M3l6UWZ5V3l0ZGZDNlFxOFlFOUpOa1B6em03X1Z4U1VRb1k2dw?oc=5","date":"2026-03-03","type":"pipeline","source":"Stock Titan","summary":"RxSight (RXST) CCO gains 6,261 shares, withholds 2,580 for taxes - Stock Titan","headline":"RxSight (RXST) CCO gains 6,261 shares, withholds 2,580 for taxes","sentiment":"neutral"},{"date":"2026-02-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxObTk4ZGJMZGY0ZHFsLUV0OHpYX3B6UEVaVnVOeGdkU2Z6X0NFa01qdFNqbGhvd1RYUEd2R19YY3JHZEZFdXVrQkVRcnNVQU54MURveUlwN0xGVVBIQzFTZjdoVEF3aFhMdnEySzVRTWpMaFBuUl9jMUk5MkU0M3d2VWx6UzR6NjZtLVNVRERXYlNUZnFyV2ZhajN5Vlk3Y0xBb184VnRqakRtS0NQdEZfRUxLRTl5OGVVQXBVTC03bUJCQUtFeEczVUROeXpHVUp6Q1FUb180VGxkVy12Y0hPTTl6SEp1TEZJZUFSZTNfOHFTNnNZWDVhbDJtSFZOLWkzTVQ3SnRnVDVTNzROa3VGczlPTnh1clpt?oc=5","date":"2026-02-21","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Senseonics Holdings (SENS) and Novo Nordisk (NVO) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Senseonics Holdings (SENS) and Novo Nordisk (NVO)","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxPRXhWV09Ja0R0WXhrZVFzSzRieWpEdWdLMjBnZWh4QllncW45ejNocEZha3pqaGtmdnd1bm1EcWFsakFHSzhMS1VWRzlvU2VERU5kbWk4NzJyT2huT1lyN0lhYW9DbXg0X0ZrXzNuRzkyMjYxaVZtWHNFTUZ1ZWE1bGxyRzZmdzkxY3h3YXVHYmRxSVh0TXJ3UTZzZDNGc21mTlZlcUcwWEkwelI5dlQyQnRtNXcySTFyLVUtSkdLNWdOYlE2U0E5Z2ZibE92bXp0VkFXUGwxaktwR3RrNWlsZk5jR3lFNmJJdlpLLVdaZ25jVURJTm5zbm40OWJmTUV2Sk1mWno0ZGNSSDdZMm52cUxLcG55NkJ1RC1pWTYydw?oc=5","date":"2025-09-22","type":"pipeline","source":"GlobeNewswire","summary":"RXSIGHT FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire","headline":"RXSIGHT FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPaHVNaFpEd2lFaElnQU9HUlFHN291V2lGX2pMY3lWcVgtcnhOSU9tX2dQWjlXU3NkT3VNb1pVdEtDVkYwZDgxSjlNT3RON1dMNnExNHVLbGtYTGlCUHByNnFXRlNrQUMyTldDMmlOWTlOcXNSaWd3SV96cGF2a05PdjVpMGVtN2JBTWJoSnI4ZFIwUFRtZ1ZCandjbWRYUzFFMjBUX3VtV3VsMnp6QS1nZktn?oc=5","date":"2025-07-09","type":"pipeline","source":"Seeking Alpha","summary":"RxSight's Revised Guidance Reflects Deeper Market Shifts (Rating Downgrade) (NASDAQ:RXST) - Seeking Alpha","headline":"RxSight's Revised Guidance Reflects Deeper Market Shifts (Rating Downgrade) (NASDAQ:RXST)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPRGZTU2dyOUN4VWdDOV9yTkJiWThkZk9aVy1hYzVSYzZ1Q3AtT2lRd3ZxYmNsUE1qNHpNdHdWcEtZMXY3QVhiejFvdzlwb1g5eVo2T212dEpmT0RwUWk3Qml3UGNHMC1vNDFvWlRVbDMyOXNLeTNUSVIteVRORWxuMVZSZWpmVXJDSUhGUWZJRlpxcUc2NXc?oc=5","date":"2025-06-07","type":"pipeline","source":"Seeking Alpha","summary":"RxSight Stock: Valuation Blowout Creates Opportunity (NASDAQ:RXST) - Seeking Alpha","headline":"RxSight Stock: Valuation Blowout Creates Opportunity (NASDAQ:RXST)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQQm1aOXl3VlU2Tnc3Q3ZQMi02MEo4MGZYUFVpTExMQjZJaTNmQ0FZd0tJZ3V6TnVGa1paLUFkS0g0RHJVRWw5UnFLS2hjdENPcnJ1UXpFLUJ3U1YzZ0hiTi1CZWtCR2NKellEVFhuWXF1YVk1QXRXQk1PQXNpS3hjRmJzbHhhM0lyckhYWGdCb0VSRFZSQkNaVmxDelltRU1XMW1JdUhYSjVSUQ?oc=5","date":"2024-08-13","type":"pipeline","source":"Seeking Alpha","summary":"Investing In The Future Of Cataract Surgery: The RxSight Advantage (NASDAQ:RXST) - Seeking Alpha","headline":"Investing In The Future Of Cataract Surgery: The RxSight Advantage (NASDAQ:RXST)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE9MZndtcTJ4ZGwzOFdEMGFrWHVLT1VGdFlPeldpZHV3MG9FcXpyaUxQVnNacmhzVjczNHUxZnBVSDJnMU4yWnRfWlZPMWtxTTI1?oc=5","date":"2023-12-06","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE1seFdiZzY5YWs0S0pWVXVDTzZqejFRc0E0aGE2alU0aWxaazI3UzFKWmRMYThUR1kxLVhDX0xLdUpZc3J2OTU3ZjF0LXZiYjZ1MjNkNElfa1BEQQ?oc=5","date":"2021-07-31","type":"pipeline","source":"MarketBeat","summary":"RxSight (RXST) Stock Price, News & Analysis - MarketBeat","headline":"RxSight (RXST) Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Alcon","Johnson & Johnson","Abbott Laboratories"],"therapeuticFocus":["Ophthalmic Devices","Cataract Surgery"],"financials":{"source":"sec_edgar","revenue":134479000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":134479000,"period":"2025-12-31"},{"value":139927000,"period":"2024-12-31"},{"value":139927000,"period":"2024-12-31"},{"value":89077000,"period":"2023-12-31"},{"value":89077000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":38549000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-38944000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":311814000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":7.17,"previousClose":6.76,"fiftyTwoWeekHigh":17.52,"fiftyTwoWeekLow":5.9,"fiftyTwoWeekRange":"5.9 - 17.52","fiftyDayAverage":7.77,"twoHundredDayAverage":9.19,"beta":1.21,"enterpriseValue":61872424,"forwardPE":-14.8,"priceToBook":1.07,"priceToSales":2.2,"enterpriseToRevenue":0.46,"enterpriseToEbitda":-1.38,"pegRatio":0,"ebitda":-44925000,"ebitdaMargin":-33.4,"freeCashflow":-1625250,"operatingCashflow":-15511000,"totalDebt":11040000,"debtToEquity":4,"currentRatio":10.95,"returnOnAssets":-9.6,"returnOnEquity":-14,"analystRating":"3.1 - Hold","recommendationKey":"hold","numberOfAnalysts":7,"targetMeanPrice":10.21,"targetHighPrice":13,"targetLowPrice":8,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":5.6,"institutionHeldPercent":90,"sharesOutstanding":41266335,"floatShares":36928418,"sharesShort":5066398,"shortRatio":6.3,"shortPercentOfFloat":12.3,"epsTrailing":-0.95,"epsForward":-0.48,"revenuePerShare":3.29,"bookValue":6.68,"officers":[{"age":62,"name":"Dr. Ronald M. Kurtz M.D.","title":"President, CEO & Director"},{"age":50,"name":"Dr. Ilya  Goldshleger Ph.D.","title":"Chief Operating Officer"},{"age":64,"name":"Mr. Eric J. Weinberg","title":"Chief Business Development Officer"},{"age":null,"name":"Mr. Mark  Wilterding","title":"Chief Financial Officer"},{"age":null,"name":"Mr. Oliver  Moravcevic","title":"Vice President of Investor Relations"},{"age":null,"name":"Mr. Jim  Schindler","title":"Executive VP & General Counsel"},{"age":null,"name":"Mr. Scott  Gaines","title":"Chief Customer Officer"},{"age":null,"name":"Ms. Maureen  O'Connell","title":"Executive VP of Clinical & Regulatory Affairs"}],"industry":"Medical Devices","irWebsite":"","website":"https://rxsight.com","phone":"949 521 7830"}}